{"id":2691,"date":"2023-01-16T13:12:37","date_gmt":"2023-01-16T18:12:37","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&#038;p=2691"},"modified":"2025-06-18T16:00:34","modified_gmt":"2025-06-18T21:00:34","slug":"analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/en\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/","title":{"rendered":"Analysis of access to innovative medicines in Peru compared to other OECD countries"},"content":{"rendered":"<p>This document&#8217;s main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.<\/p>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-76d52a6b-2d24-4a12-bd07-86ad07212c8e\" href=\"https:\/\/fifarma.org\/wp-content\/uploads\/2023\/01\/Analysis-of-acces-to-innovative-medicines-in-Peru-compared-to-other-OECD-countries.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Preview<\/a><\/div>\n\n\n<div class=\"taxonomy-idioma wp-block-post-terms\"><a href=\"https:\/\/fifarma.org\/en\/idioma\/english\/\" rel=\"tag\">English<\/a><\/div>\n\n<div class=\"taxonomy-ano wp-block-post-terms\"><a href=\"https:\/\/fifarma.org\/en\/ano\/2019\/\" rel=\"tag\">2019<\/a><\/div>\n\n<div class=\"taxonomy-etiquetas-publicacion wp-block-post-terms\"><a href=\"https:\/\/fifarma.org\/en\/etiquetas-publicacion\/medicamentos-innovadores\/\" rel=\"tag\">Iinnovative medication<\/a><\/div>\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"author":24,"parent":0,"template":"","ano":[46],"idioma":[45],"etiquetas-publicacion":[28],"categoria-publicacion":[30],"class_list":["post-2691","publicaciones","type-publicaciones","status-publish","hentry","ano-46","idioma-english","etiquetas-publicacion-medicamentos-innovadores","categoria-publicacion-infografia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.7 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Analysis of access to innovative medicines in Peru compared to other OECD countries<\/title>\n<meta name=\"description\" content=\"This document&#039;s main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/publications\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analysis of access to innovative medicines in Peru compared to other OECD countries\" \/>\n<meta property=\"og:description\" content=\"This document&#039;s main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/publications\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-18T21:00:34+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\\\/\",\"name\":\"Analysis of access to innovative medicines in Peru compared to other OECD countries\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2023-01-16T18:12:37+00:00\",\"dateModified\":\"2025-06-18T21:00:34+00:00\",\"description\":\"This document's main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Analysis of access to innovative medicines in Peru compared to other OECD countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Analysis of access to innovative medicines in Peru compared to other OECD countries","description":"This document's main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/publications\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/","og_locale":"en_US","og_type":"article","og_title":"Analysis of access to innovative medicines in Peru compared to other OECD countries","og_description":"This document's main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.","og_url":"https:\/\/fifarma.org\/en\/publications\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/","og_site_name":"FIFARMA","article_modified_time":"2025-06-18T21:00:34+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/","url":"https:\/\/fifarma.org\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/","name":"Analysis of access to innovative medicines in Peru compared to other OECD countries","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2023-01-16T18:12:37+00:00","dateModified":"2025-06-18T21:00:34+00:00","description":"This document's main objective is to valuate access to innovative medicines in Peru and compare it with other OECD countries.","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-acces-to-innovative-medicines-in-peru-compared-to-other-oecd-countries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"Analysis of access to innovative medicines in Peru compared to other OECD countries"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Latin American Federation of the Pharmaceutical Industry","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones\/2691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=2691"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/ano?post=2691"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/idioma?post=2691"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/etiquetas-publicacion?post=2691"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categoria-publicacion?post=2691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}